Lupin has announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States.
The product is a bioequivalent version of Victoza Injection, 18 mg/3 mL (6 mg/mL), originally developed by Novo Nordisk Inc. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and paediatric patients aged 10 years and older with type 2 diabetes mellitus.
According to IQVIA MAT data from August 2025, the reference listed drug (RLD) Victoza had an estimated annual sale of USD 350 million in the United States.
Spiro Gavaris, President – U.S. Generics, Lupin, said, “We are pleased to launch Liraglutide Injection in the U.S. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients.”
The post Lupin launches generic Liraglutide Injection in the U.S. market appeared first on Express Pharma.